BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Cisplatin: trial readouts and FDA decisions

18 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 27 readout(s) in the last 180 days and 1 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, Merck Sharp & Dohme LLC, Innovent Biologics (Suzhou) Co. Ltd., CSPC Megalith Biopharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Qilu Pharmaceutical Co., Ltd., Karyopharm Therapeutics Inc, Boehringer Ingelheim, CSPC Megalith Biopharmaceutical Co., Ltd., Nanjing Leads Biolabs Co., Ltd, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Akeso, RemeGen Co., Ltd., CStone Pharmaceuticals, Seagen, a wholly owned subsidiary of Pfizer, Bristol-Myers Squibb, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Taiho Oncology, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Takeda, Bio-Thera Solutions, mAbxience Research S.L., Regeneron Pharmaceuticals, Hoffmann-La Roche, Jazz Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Avyxa Holdings, LLC, CSPC Megalith Biopharmaceutical Co., Ltd., Nanjing Leads Biolabs Co., Ltd, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Taiho Oncology, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd, TJ Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Avyxa Holdings, LLC, CSPC Megalith Biopharmaceutical Co.,Ltd., Nanjing Leads Biolabs Co.,Ltd, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Genelux Corporation, Shanghai Runshi Pharmaceutical Technology Co., Ltd, Taiho Oncology, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, TJ Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Avyxa Holdings, LLC. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-11-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell LungResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancerrecruiting170
2026-11-30 est.P2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoNon-Small Cell Lung Cancernot yet recruiting120
2026-12 est.P2/P3Karyopharm Therapeutics Inc KPTIQNCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruiting501
2026-12-10 est.P3Boehringer IngelheimNCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With StandarLung Cancer, Non-squamous, Non-small Cellactive not recruiting428
2026-12-28 est.P1/P2Nanjing Leads Biolabs Co.,LtdNCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaAdvanced Neuroendocrine Carcinomarecruiting178
2026-12-30 est.P3Janssen Research & Development, LLCNCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderUrinary Bladder Neoplasmsactive not recruiting518
2026-12-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting93
2026-12-31 est.P1/P2AkesoNCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsAdvanced Malignant Tumorsactive not recruiting154
2026-12-31 est.P3RemeGen Co., Ltd.NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaUrothelial Carcinoma; HER2-expressingrecruiting452
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-11 est.P3AstraZeneca AZNNCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGMetastatic Non-small Cell Lung Canceractive not recruiting768
2027-01-29 est.P3Seagen, a wholly owned subsidiary of PfizerNCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Urothelial Carcinomaactive not recruiting412
2027-01-31 est.P3Merck Sharp & Dohme LLC MRKNCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99Urinary Bladder Neoplasmsactive not recruiting520
2027-02-05 est.P2Bristol-Myers Squibb BMYNCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously UnNon-Small Cell Lung Canceractive not recruiting76
2026-12 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients WiNon-Small Cell Lung Canceractive not recruiting432
2026-12 est.P3Genelux Corporation GNLXNCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/RefractoryPlatinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primarrecruiting186
2027-02 est.P2Genelux Corporation GNLXNCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerAdvanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Mrecruiting142

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-06-17Complete response letterapproved sinceAvyxa Holdings, LLCCisplatinCRL 2026-06-17: Avyxa Holdings, LLC NDA 220748 (Cisplatin Injection)

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Unresectable Locally Advanced or Metastatic Solid Tumorsnot yet recruiting380
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-10 est.P2Qilu Pharmaceutical Co., Ltd.NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerCLDN18.2-positive Advanced Biliary Tract Cancernot yet recruiting120
2026-10 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2026-10 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerAdvanced or Metastatic Non-small Cell Lung Cancerrecruiting248
2026-09-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNon-Small Cell Lung Canceractive not recruiting506
2026-09-22P3Takeda TAKNCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)completed354
2026-09 est.P2/P3Bio-Thera SolutionsNCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerCervical Cancerrecruiting526
2026-08-31 est.P3mAbxience Research S.L.NCT06687369 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung CancerNon Squamous Non Small Cell Lung Canceractive not recruiting726
2026-08-24 est.P2Regeneron Pharmaceuticals REGNNCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in AResectable Non-small Cell Lung Canceractive not recruiting195
2026-08 est.P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung Cancerrecruiting110
2026-07-31P3Hoffmann-La RocheNCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancercompleted11
2026-07-30 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)EGFR-mutated Locally Advanced or Metastatic NSCLCrecruiting380
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-07-10P3AstraZeneca AZNNCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete TuNon-small Cell Lung Canceractive not recruiting25
2026-07-06P3AstraZeneca AZNNCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatCarcinoma; Non-Small-Cell Lungactive not recruiting341
2026-07 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.Neuroendocrine Carcinomaunknown93
2026-06-30 est.P2Qilu Pharmaceutical Co., Ltd.NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsAdvanced Solid Tumornot yet recruiting360
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610
2026-06-09P3AstraZeneca AZNNCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small CLocally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting454
2026-06-01P3AstraZeneca AZNNCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Canceractive not recruiting1246
2026-08-30 est.P2TJ Biopharma Co., Ltd.NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated LocaNon Small Cell Lung Canceractive not recruiting150
2026-08 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)Non-small Cell Lung Canceractive not recruiting432
2026-07-07P2AstraZeneca AZNNCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsLung Canceractive not recruiting76
2026-05-31P2AkesoNCT05932212 AK104 for Recurrent or Metastatic Vulvar CancerVulvar Cancerterminated20

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.